Comparison of 10 mL 0.15% vs 20 mL 0.25% bupivacaine boluses for continuous adductor canal block in total knee arthroplasty: a randomized non-inferiority trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 40393775.
- Also identified by DOI 10.1136/rapm-2025-106587.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Different concentrations and volumes of local anesthetic boluses are used for continuous adductor canal block. We hypothesized that a 10 mL 0.15% bupivacaine bolus would provide non-inferior pain relief to a 20 mL 0.25% bupivacaine bolus for continuous adductor canal block as part of comprehensive multimodal analgesia. 140 patients undergoing total knee arthroplasty were randomly allocated to receive either a 20 mL bolus of 0.25% bupivacaine (20/0.25 bupi group) or a 10 mL bolus of 0.15% bupivacaine (10/0.15 bupi group). Both groups received continuous adductor canal block with 0.15% bupivacaine (5 mL/hour), local infiltration analgesia, and interspace between the popliteal artery and capsule of the knee block. The primary outcomes were average knee-pain scores 6 and 12 hours postoperatively; the non-inferiority margin was a score difference of 1. Secondary outcomes included rest and movement pain scores, morphine consumption, and time to first rescue analgesia. The median knee-pain scores for the 20/0.25 and 10/0.15 bupi groups were 0 (0 to 1) and 0 (0 to 2), respectively, after 6 hours and 2 (1 to 2) and 2 (1 to 3), respectively, after 12 hours. The median treatment difference (10/0.15 bupi ̶ 20/0.25 bupi) was 0 (95% CI -0.45 to 0.45) at both time points, with neither interval exceeding the non-inferiority margin. No clinical differences were observed in secondary outcomes. A 10 mL 0.15% bupivacaine bolus in continuous adductor canal block offers comparable average knee-pain relief 6 and 12 hours after total knee arthroplasty to a 20 mL 0.25% bupivacaine bolus. NCT06179628.